- Trials with a EudraCT protocol (251)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
251 result(s) found for: Ligand.
Displaying page 1 of 13.
EudraCT Number: 2008-001973-14 | Sponsor Protocol Number: KUN2006-3699 | Start Date*: 2009-04-27 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: TLR ligand matured dendritic cell vaccination in melanoma patients: the key towards a more potent immune induction? | ||
Medical condition: Our study population consists of HLA-A2.1 positive melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node m... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003733-25 | Sponsor Protocol Number: CHUBX2013/27 | Start Date*: 2014-12-03 |
Sponsor Name:CHU de BORDEAUX | ||
Full Title: Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematous | ||
Medical condition: systemic lupus erythematous | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004128-32 | Sponsor Protocol Number: KZM-PSMA-01 | Start Date*: 2017-12-01 |
Sponsor Name:Fakultní nemocnice Plzeň | ||
Full Title: Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11 | ||
Medical condition: prostatic carcinoma higly suspected or its staging or restaging | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001688-35 | Sponsor Protocol Number: APACHE | Start Date*: 2016-09-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors | |||||||||||||
Medical condition: Advanced and relapsed germ cell tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000106-37 | Sponsor Protocol Number: 37.07.-92906 | Start Date*: 2008-08-28 | |||||||||||
Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital | |||||||||||||
Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris | |||||||||||||
Medical condition: Psoriasis vulgaris (Plaque-Typ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000713-11 | Sponsor Protocol Number: CV149-208 | Start Date*: 2007-07-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers i... | |||||||||||||
Medical condition: Biomarkers of inflammation and platelet activation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021846-23 | Sponsor Protocol Number: 20080585 | Start Date*: 2010-11-24 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer | |||||||||||||
Medical condition: Castrate-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004156-39 | Sponsor Protocol Number: no sponsor | Start Date*: 2005-11-18 |
Sponsor Name:Dept. of Neurology Vienna | ||
Full Title: Brain serotonin 5-HT1A receptor binding in human mesial temporal lobe epilepsy measured by positron emission tomography and [11C]WAY-100635 | ||
Medical condition: Application of [11C]WAY-100635, a brain serotonin 5-HT1A receptor ligand, in patients with mesial temporal lobe epilepsy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006773-38 | Sponsor Protocol Number: TSPOC5FOR2022 | Start Date*: 2022-11-29 |
Sponsor Name:Medizinische Einrichtungen des Berzirks Oberpfalz | ||
Full Title: TSPO ligands in the treatment of depression: proof-of-concept of efficacy and underlying mechanisms of action | ||
Medical condition: Unipolar/bipolar depressive disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004249-33 | Sponsor Protocol Number: A8881001 | Start Date*: 2005-12-14 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ... | |||||||||||||
Medical condition: Overactive bladder syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003152-37 | Sponsor Protocol Number: MK3475-A18/ENGOT-cx11/GOG-3047 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
Full Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047) | |||||||||||||
Medical condition: High-risk locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015737-73 | Sponsor Protocol Number: 2009-015737-73 | Start Date*: 2010-02-04 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients | ||
Medical condition: Our study population consists of melanoma patients, with proven expression of melanoma associated tumor antigens gp100 and tyrosinase. Melanoma patients with regional lymph node metastasis in whom ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018279-99 | Sponsor Protocol Number: HUM07-066 | Start Date*: 2010-05-05 |
Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg | ||
Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis | ||
Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003857-27 | Sponsor Protocol Number: LUPSA | Start Date*: 2020-01-23 |
Sponsor Name:Radboudumc | ||
Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study. | ||
Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004448-37 | Sponsor Protocol Number: PET-CFS-1 | Start Date*: 2015-09-30 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Visualising neuroinflammation in chronic fatigue syndrome patients | ||
Medical condition: Chronic Fatigue Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-003235-31 | Sponsor Protocol Number: Prof. Franz Weidinger | Start Date*: 2005-01-31 |
Sponsor Name:Div. of Cardiology, Innsbruck Medical University | ||
Full Title: Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome | ||
Medical condition: Acute coronary syndrome; patients with NSTEMI | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-003616-31 | Sponsor Protocol Number: MK-7339-013 | Start Date*: 2020-10-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-... | |||||||||||||
Medical condition: Limited-Stage Small Cell Lung Cancer (LS-SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020343-13 | Sponsor Protocol Number: ESTEVE-SIGM-106 | Start Date*: 2010-06-21 | |||||||||||
Sponsor Name:Laboratorios del Dr Esteve S.A | |||||||||||||
Full Title: A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young health... | |||||||||||||
Medical condition: Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004906-15 | Sponsor Protocol Number: 0730302 | Start Date*: 2009-01-05 | |||||||||||
Sponsor Name:CHU Toulouse | |||||||||||||
Full Title: EVALUATION DE LA CAPTATION D’UN RADIOLIGAND DES TRANSPORTEURS DE LA DOPAMINE CHEZ DES SUJETS ATTEINTS DE LA MALADIE DE PARKINSON ET PRESENTANT OU NON DES DOULEURS EN RAPPORT AVEC CETTE PATHOLOGIE | |||||||||||||
Medical condition: Maladie de Parkinson | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002502-75 | Sponsor Protocol Number: P-pVAC-SARS-CoV-2 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults | |||||||||||||
Medical condition: healthy subjects obtaining a potential vaccine for COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
